QNCX - Quince Therapeutics Inc
IEX Last Trade
0.686
-0.007 -1.064%
Share volume: 188,259
Last Updated: Fri 30 Aug 2024 09:47:17 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$0.69
-0.01
-1.05%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
4.70%
1 Month
-6.75%
3 Months
-16.98%
6 Months
-48.43%
1 Year
-46.43%
2 Year
-61.40%
Key data
Stock price
$0.69
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.51 - $1.43
52 WEEK CHANGE
-$0.47
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
Company detail
CEO:
Region: US
Website: cortexyme.com
Employees: 12
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: cortexyme.com
Employees: 12
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
cortexyme is developing therapeutics based on data supporting a new theory of the cause of alzheimer's and other degenerative disorders. cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration and beta amyloid production. the target has been validated in a number of animal models and cortexyme is currently moving a proprietary small molecule towards human clinical testing.
Recent news